New publication – Attana’s technology employed to understand how the human secretome can induce cardiac regeneration and repair post myocardial infarction
A new paper has been published in the International Journal of Molecular Science. In the paper, almost 1000 human human secretome proteins where screened to check if they could be involved in regeneration and repair of cardic cells post infarcts, thereby provide a better treatment than what is available today. 12 proteins demonstrated promising properties. Attana's QCM technology and expertise was employed to further understand and select the most suitable protein based on cell-based kinetic interaction characterisation and to demonstrated that the proteins interacts with different receptors.
Heart failure is a major cause of mortality worldwide and myocardial infarction is a common cause which results in the loss of a substantial number of cardiomyocytes. The available therapies for these patients can only slow down disease progression and reverse limited aspects of cardiac dysfunction. A treatment that can repair and stimulate growth of new cardiac cells would thus provide an improved treatment.
Paracrine factors can induce cardiac regeneration and repair post myocardial infarction by stimulating proliferation of cardiac cells. In the paper, a human secretome library consisting of 923 growth factors, cytokines, and proteins was screened with respect to proliferation rate of human cardiac progenitor cells. From this screen, 12 proteins displayed promising results. Two proteins, FGF9 and FGF16, were especially interesting. Both belong to the same FGF subfamily, share high sequence identity, and are described to have similar receptor preferences. However, FGF16 was shown to be specific for proliferation of cardiac progenitor cells, whereas FGF9 also proliferated human cardiac fibroblasts. Attana biosensor analysis of receptor preferences and quantification of receptor abundances suggested that FGF16 and FGF9 interact with different FGF receptors on the cardiac progenitor cells and cardiac fibroblasts. Taken together, the data suggest that FGF16 could be a suitable paracrine factor to induce cardiac regeneration and repair.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact email@example.com.